Capstone Investment Advisors
SMMT icon

Capstone Investment Advisors’s Summit Therapeutics SMMT Stock Holding History

Capstone Investment Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-37,238
Closed -$175K – 1917
2020
Q4 		$175K Buy
+37,238
New +$158K ﹤0.01% 1474

Other funds holding SMMT

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Capstone Investment Advisors's SMMT Position: Q1 2021 in Review

Capstone Investment Advisors sold out of Summit Therapeutics (SMMT) in Q1 2021, closing a stake of 37,238 shares — an estimated $175K sold.

Capstone Investment Advisors first reported a position in SMMT in Q4 2020 and held it in 1 quarter. The position peaked at $175K in Q4 2020. 41 funds tracked by Wall St. Rank hold SMMT as of Q1 2021.

  • Capstone Investment Advisors reported no remaining Summit Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Capstone Investment Advisors sold 37,238 Summit Therapeutics shares in Q1 2021, an estimated $175K.
  • Capstone Investment Advisors first reported a position in Summit Therapeutics in Q4 2020 and held it in 1 quarter.
  • Capstone Investment Advisors's Summit Therapeutics position peaked at $175K in Q4 2020.
  • 41 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2021.

Based on Capstone Investment Advisors's 13F filing for Q1 2021, filed 17 May 2021.